dMed Biopharma, a Shanghai CRO that offers clinical trial services in China, the US and the EU, completed a Series B financing of nearly $50 million, led by Vivo Capital and joined by Legend Capital, Qiming Venture Partners and Lilly Asia Ventures. Launched three years ago, dMed considers itself a “next-gen” clinical CRO with efficient operations, IT services and expertise in cross-border global trials. The company has 600 employees. Recently, dMed acquired Target Health, a full service New York-based CRO, to expand its global offerings and add new technologies.
Source: China Biotoday